» Articles » PMID: 23578794

Pharmacokinetics of Ertapenem in Burns Patients

Overview
Date 2013 Apr 13
PMID 23578794
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

The aims of this study were to evaluate pharmacokinetic (PK) parameters of total and unbound ertapenem (ERT) in burns patients and to identify which covariates influence these PK parameters. ERT plasma concentrations were measured in burns patients (n = 8) who received a 0.5-h infusion of ERT (1000 mg) every 24 h. PK parameters were estimated by a non-compartmental approach and the influence of covariates was estimated by multivariate analysis using a population approach. Clearance (CL) and the volume of distribution (V) of total ERT were lower than the results for unbound ERT [CL, 22.2 ± 5.6 mL/min vs. 279.4 ± 208.2 mL/min; V, 9.7 ± 1.4L vs. 120.6 ± 130.6L (mean ± standard deviation)]. Creatinine clearance (CL(Cr)) and the burned surface area (BSA) were the covariates identified that significantly (P<0.01) affected the pharmacokinetics of total ERT [CL (L/h)=0.373 +{0.00666 x CL(Cr) (mL/min)}] and unbound ERT [peripheral volume of distribution (L) = 3.05 + {0.959 x BSA (% of the total body surface)}], respectively. The influences of albuminaemia, glomerular filtration and burn wound on ERT pharmacokinetics are proposed to explain these results. These first results support that the ERT plasma concentration should be closely monitored particularly for patients with high values of BSA and/or CL(Cr) to avoid suboptimal exposure.

Citing Articles

Risk Factors Associated with Antibiotic Exposure Variability in Critically Ill Patients: A Systematic Review.

Gras-Martin L, Plaza-Diaz A, Zarate-Tamames B, Vera-Artazcoz P, Torres O, Bastida C Antibiotics (Basel). 2024; 13(9).

PMID: 39334976 PMC: 11428266. DOI: 10.3390/antibiotics13090801.


Augmented Renal Function in Burn Patients: Occurrence and Discordance With Commonly Used Methods to Assess Renal Function.

Mueller S, Blass B, Molina K, Gibson C, Krsak M, Kohler A J Burn Care Res. 2023; 44(6):1298-1303.

PMID: 37450897 PMC: 11491612. DOI: 10.1093/jbcr/irad107.


Pharmacokinetic-Pharmacodynamic Evaluation of Ertapenem for Patients with Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia.

Bader J, Lakota E, Dale G, Sader H, Rex J, Ambrose P Antimicrob Agents Chemother. 2019; 63(6).

PMID: 30962339 PMC: 6535521. DOI: 10.1128/AAC.00318-19.


Population Pharmacokinetic Analyses for Ertapenem in Subjects with a Wide Range of Body Sizes.

Lakota E, Landersdorfer C, Zhang L, Nafziger A, Bertino Jr J, Bhavnani S Antimicrob Agents Chemother. 2018; 62(10).

PMID: 30061283 PMC: 6153805. DOI: 10.1128/AAC.00784-18.


Pharmacokinetic Modeling and Limited Sampling Strategies Based on Healthy Volunteers for Monitoring of Ertapenem in Patients with Multidrug-Resistant Tuberculosis.

van Rijn S, Zuur M, van Altena R, Akkerman O, Proost J, de Lange W Antimicrob Agents Chemother. 2017; 61(4).

PMID: 28137814 PMC: 5365678. DOI: 10.1128/AAC.01783-16.